Cargando…
Inflammation is responsible for systemic bone loss in patients with seropositive rheumatoid arthritis treated with rituximab
BACKGROUND/AIMS: We investigated the effect of rituximab on systemic bone metabolism in patients with seropositive rheumatoid arthritis (RA). METHODS: Twenty seropositive patients with RA were enrolled and administered one cycle of rituximab. If RA became active for > 6 months after the first rit...
Autores principales: | Lim, Mie Jin, Jung, Kyong-Hee, Kwon, Seong-Ryul, Park, Won |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Association of Internal Medicine
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10636556/ https://www.ncbi.nlm.nih.gov/pubmed/37867140 http://dx.doi.org/10.3904/kjim.2023.080 |
Ejemplares similares
-
Seronegative and seropositive rheumatoid arthritis treated with rituximab
por: Velloso Feijoo, Maria Luisa, et al.
Publicado: (2012) -
Palisaded Neutrophilic Granulomatous Dermatitis in a Patient with Systemic Sclerosis-Rheumatoid Arthritis Overlap Syndrome
por: Jung, Kyong-Hee, et al.
Publicado: (2017) -
Successful Treatment of Rituximab-Associated Palmoplantar Pustulosis With Apremilast in a Patient With Seropositive Rheumatoid Arthritis
por: Haller, Christoph, et al.
Publicado: (2021) -
A Comparison of Three Different Guidelines for Osteoporosis Treatment in Patients with Rheumatoid Arthritis in Korea
por: Yoon, Jiyeol, et al.
Publicado: (2010) -
Rituximab for Rheumatoid Arthritis
por: Cohen, Marc D., et al.
Publicado: (2015)